Effect of Adalimumab on Work Ability Assessed in Rheumatoid Arthritis Disease Patients in Saudi Arabia (AWARDS)

Waleed Hussain¹, Nahid Janoudi², Abdulsalam Noorwali³,⁴, Narges Omran⁴, Matouqa Baamer⁵, El Hussain Assiry⁶, Hanan Alrayes⁷, Hanan Alosaimi⁸, Ashraf Ibrahim⁸, Shereen Gohary⁸, Joan Mignuet⁸ and Hani Almoallim *¹,²,³,⁸

¹Department of Medicine, Heraa General Hospital, Makkah, Saudi Arabia
²Department of Medicine, Dr. Soleiman Fakeeh Hospital, Jeddah, Saudi Arabia
³Department of Medicine, Umm Alqura University, Makkah, Saudi Arabia
⁴Department of Medicine, Alnoor General Hospital, Makkah, Saudi Arabia
⁵Department of Medicine, King Abdulaziz Hospital and Oncology Center, Jeddah, Saudi Arabia
⁶Department of Medicine, Aseer Center Hospital, Abha, Saudi Arabia
⁷Department of Medicine, Riyadh Military Hospital, Riyadh, Saudi Arabia
⁸Alzaidi Chair of Research in Rheumatic Diseases, Medical College, Umm Alqura University, Makkah, Saudi Arabia

Abstract: Objectives: Rheumatoid arthritis (RA) is a chronic disabling disease that can jeopardize the ability of affected individuals to participate in paid work. Our objective was to evaluate the effectiveness of a 6-month course of tumor necrosis factor (TNF) antagonist (adalimumab) on work ability, overall health, and fatigue in RA patients.

Methods: Between October 2012 and February 2014, this prospective, observational study enrolled 63 consecutive patients with established adult RA at outpatient clinics in Makkah, Jeddah, Riyadh and Abha (Saudi Arabia). Patients received subcutaneous injections of adalimumab (40 mg every 2 weeks). Outcomes were measured at baseline and 6 months using the following tools: Work Productivity and Activity Impairment (WPAI), Health Assessment Questionnaire Disability Index (HAQ-DI), Fatigue Severity Scale (FSS), Visual Analog Scale for Fatigue (VAS-F), and work disability self-assessment.

Results: All outcomes showed improvements after 6 months of adalimumab therapy. Significant improvements from baseline were observed in absenteeism (64% ± 11.62 to 11.60% ± 11.17 [p<0.0001]), presenteeism (62.15% ± 20.11 to 34.92% ± 20.61 [p<0.0001]), overall work impairment (69.08% ± 18.86 to 40.73% ± 22.29 [p<0.0001]), overall activity impairment (68.46% ± 18.58 to 36.46% ± 20.79 [p<0.0001]), HAQ score (1.69 ± 0.57 to 0.81 ± 0.61 [p<0.0001]), and FSS score (47.08 ± 9.55 to 27.86 ± 13.43 [p<0.0001]).

Conclusion: A 6-month course of adalimumab improved work ability, fatigue, and overall health assessments in patients with established RA. Our findings encourage randomized controlled trials investigating the cost-effectiveness and long-term effects of TNF inhibitors on work disability.

Keywords: Adalimumab, health assessment, rheumatoid arthritis, tumor necrosis factor (TNF) inhibitor, work ability.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic disabling disease that threatens the ability of affected individuals to participate in paid work [1]. RA patients not only suffer from pain when disease activity is high, but also experience an impaired quality of life (QoL) and increased prevalence of fatigue [2,3]. Therefore, both newly diagnosed and longstanding RA patients have a high prevalence of work disability, which is associated with a significant socioeconomic burden [4,5].

Indeed, it was demonstrated that approximately 40% of new and 60% of established RA patients are unable to work [6,7].

In order to reduce the pain and suffering of RA patients, several novel treatment strategies have been developed. In this regard, tumor necrosis factor (TNF)-blocking agents were shown to be effective in reducing disease activity, slowing disease progression, and improving QoL [8,9]. In fact, a recent study reported considerably longer periods of work and continuous employment in RA patients receiving adalimumab in comparison to those receiving conventional treatment with disease-modifying anti-rheumatic drugs (DMARDs) [10]. However, even though recent emphasis has been placed on improving work-related outcomes in RA
patients [11], work ability in those receiving TNF agonists has not been fully investigated.

Recently, progress has been made in measuring work ability in RA patients. Indeed, the Work Productivity and Activity Impairment (WPAI) questionnaire is a validated tool for measuring the effect of RA on both work and non-work activities [12]. This assessment tool consists of six items that are used to produce percentage scores in four distinct domains (i.e., absenteeism, presenteeism, overall work impairment, and non-work activity impairment). Prior use of this questionnaire has demonstrated that a > 7% change in the WPAI score constitutes a minimally important difference (MID) [13]. In addition, work efficiency of RA patients might be affected by fatigue, which can be measured using various self-report assessment tools, including the Fatigue Severity Score (FSS) and the Visual Analog Scale for Fatigue (VAS-F) [14,15]. Moreover, functional disability can be examined using the well-known Health Assessment Questionnaire-Disability Index (HAQ-DI) [16].

In the present study, we have evaluated the impact of adalimumab therapy on work disability among RA patients in Saudi Arabia using assessment tools. We examined the burden of RA with respect to work outcomes and QoL at baseline and after six months of adalimumab treatment. Our findings are of particular interest in the Middle East where there is a lack of data on work disability among those with RA. Thus, our investigation contributes valuable knowledge for improving the outcomes of RA patients in Saudi Arabia and around the world.

METHODS

Study Design and Patients

Between October 2012 and February 2014, this prospective, observational study consecutively enrolled 65 established RA patients. The subjects were recruited from rheumatology outpatient clinics at various hospitals in Makkah, Jeddah, Riyadh and Abha (Saudi Arabia). Patients were eligible if they were working aged (i.e., >18 and <60 years old), fulfilled the revised 2010 American College of Rheumatology (ACR) criteria for RA [17], displayed inadequate responses to at least two DMARDs, had no history of biological treatment during the preceding 6 months, showed negative results for tuberculosis (i.e., chest x-ray and skin test), and were willing to receive subcutaneous adalimumab injections (40 mg every 2 weeks) for 6 months (i.e., either self-administered or given by a qualified person). Patients with any contraindication to adalimumab treatment as outlined in the latest version of the adalimumab product label and patients with a history of using biologic treatment during the preceding 6 months were excluded from the study. All patients gave written informed consent in accordance with the Declaration of Helsinki, and the local medical ethics committees of the participating sites approved the study.

Adalimumab was prescribed according to the product label. Patients were assessed at baseline (namely, study enrollment) and at approximately 8, 16, and 24 weeks thereafter. Up to 3 follow-up visits were scheduled for each patient. The timing of these visits occurred at the discretion of the physician, and failure to adhere to the suggested follow-up schedule did not constitute a breach of the protocol. Data regarding concomitant RA medications or other diseases were recorded in the case report form at enrollment and at each follow-up. Adherence to treatment was assessed through direct interviews with patients during these visits. If treatment with adalimumab was interrupted, then the patient was treated and followed as per standard care. When patients withdrew at > 3 months but < 6 months after initiating treatment, missing follow-up data was imputed using the last observation carried forward. If the physician decided to permanently discontinue adalimumab before the end of the follow-up period, then the reason(s) for discontinuation and the new RA regimen were documented.

Assessment Tools and Outcomes

We assessed work disability in RA patients at baseline and after 6 months of adalimumab therapy using the WPAI questionnaire [12]. The questionnaire was adapted for use in the Arabic language as was done in other studies among Saudi population by our group [18]. In addition, we determined the following: 1) percentage of patients achieving an improvement of ≥ 7% in the overall WPAI score; 2) mean 6-month changes in scores for WPAI absenteeism, presenteeism, and activity impairment; 3) mean 6-month changes in HAQ-DI scores [16]; and 4) mean 6-month changes in FSS and VAS-F outcomes [14,15]. We also analyzed the percentage of patients who considered themselves to be work disabled due to RA before and after adalimumab treatment based on affirmative responses to the following question: “do you consider yourself work disabled due to RA?”

Statistical Analysis

Data were summarized using the mean, median, standard deviation, maximum, and minimum for continuous variables, whereas categorical variables were presented as frequencies and percentages. Mean 6-month changes in continuous outcomes, including the WPAI overall work impairment domain score, were analyzed using a paired student’s t-test when normally distributed, or a Wilcoxon test otherwise. The 6-month change in the percentage of patients who considered themselves as work disabled due to RA was assessed using McNemar’s test.

RESULTS

Patient Characteristics

A total of 65 RA patients were enrolled in the study, and the characteristics of these subjects are presented in Table 1. The majority of these patients were Saudi females. They had a mean age of 45.96 ± 14.42 years old and displayed a mean RA disease duration of approximately 5 years. Moreover, the average body mass index (BMI) of the study participants was 28.98 ± 7.27, with over one-third of them considered to be overweight or obese. In addition, we found that 9% of the
patients showed extra-articular manifestations of RA and that almost half presented co-morbidities, including hypertension, osteoarthritis, diabetes mellitus, osteoporosis, and dyslipidemia (19%, 12%, 10%, 7%, and 6%, respectively). Furthermore, these individuals received a mean HAQ-DI score of 1.69 ± 0.57 at baseline, which is consistent with the functional disability experienced by this population.

**Patient Therapies**

All patients participating in the study were on non-biological medications for RA prior to the start of adalimumab therapy (Table 1). Indeed, over half were taking a combination of methotrexate (MTX) and steroids, whereas fewer patients were on DMARDs other than MTX plus steroids or MTX alone (16.4% each). Notably, the mean duration of these non-biological treatments was almost 5 years.

After excluding the possibility of infection, all 65 patients started adalimumab therapy (40 mg subcutaneously, every two weeks for 6 months, pre-filled syringe). However, two patients were prematurely discontinued from adalimumab therapy: one subject lacked efficacy and the other two patients were prematurely discontinued from adalimumab treatment: one subject lacked efficacy and the other two patients were prematurely discontinued from adalimumab every two weeks for 6 months, for a combination of methotrexate (MTX) and steroids, whereas fewer patients were on DMARDs other than MTX plus steroids or MTX alone (16.4% each). Notably, the mean duration of these non-biological treatments was almost 5 years.

**Work Ability and Fatigue Assessments in RA Patients**

Outcomes of the various assessment tools employed in this study are presented in Table 2. The WPAI questionnaire revealed that absenteeism was almost halved following 6 months of adalimumab treatment in our patients (p<0.0001). In this regard, work hours missed due to RA or other reasons also decreased significantly (Table 2). Moreover, there was a significant improvement in presenteeism after therapy (p<0.0001), with RA patients showing reductions in the degree to which their disease impacted both work and non-work activities. Indeed, overall work impairment improved substantially from baseline (p<0.0001), with 79.1% of patients achieving clinically meaningful progress. Also, the percentage of overall activity impairment was significantly reduced following adalimumab treatment (p<0.0001). Additionally, the degree of functional disability (HAQ-DI) and fatigue (FSS) were found to improve significantly from baseline (both p<0.0001). Notably, 81.5% of patients achieved clinically meaningful decreases in fatigue, while 73.8% of them displayed a status of minimal or no fatigue. Finally, we observed no significant changes in VAS-F scores.

**DISCUSSION**

Patient-reported outcomes for evaluating the treatment of chronic conditions, such as RA, are gaining importance, as these evaluations are increasingly required by regulatory agencies [19-21]. Thus, we have used various patient assessment tools to demonstrate that a 6-month course of adalimumab significantly improved work ability, fatigue, and overall functional disability in patients with established RA in Saudi Arabia. Importantly, we observed high adherence rates in our patient cohort, which was probably driven by the positive outcomes and the short duration of follow-up. In this regard, the 6-month study duration was decided based on previous data, which indicated that the largest improvement for all outcome measurements was gained in the first 6 months of adalimumab treatment and was sustained in later follow-ups [22].

Our findings have indicated that significant improvement was achieved in all work ability domains after relatively short-term use of biological therapy, which is in agreement with published clinical trial data [22]. Combination therapy with DMARDs may have added benefit on our findings as shown in other studies [23]. Nevertheless, it is difficult to demonstrate an increased rate of paid employment following short-term treatment. Indeed, obtaining work can be influenced by various contributing factors (individual, environmental, and social) as well as work-related characteristics (nature of work, the workplace, and work policies) [24]. In addition, it was found that patients with longstanding RA were less likely to improve employability after effective treatment than those with early disease [7]. This fact could have influenced our results since our patients exhibited mean disease duration of approximately 5 years prior to adalimumab therapy. Indeed, such an effect on work disability could result from increased structural damage and comorbidity in late disease, whereas the role of disease activity on work disability could be reversed in early disease [23, 25, 26]. For this reason, the current objective of RA

---

**Table 1. Baseline characteristics of patients.**

| Characteristic | All Patients (n=65) |
|---------------|-------------------|
| Female (%)    | 80.3              |
| Saudi (%)     | 73.4              |
| Mean Age (years ± SD) | 45.96 ± 14.42 |
| Mean disease duration (months ± SD) | 64 ± 61.71 |
| Mean BMI (score ± SD) | 28.98 ± 7.27 |
| Overweight or obese (%) | 37.3 |
| Extra-articular RA manifestations (%) | 9.2 |
| Hypertension (%) | 20.0 |
| Osteoarthritis (%) | 12.3 |
| Diabetes (%) | 10.8 |
| Osteoporosis (%) | 7.7 |
| Mean HAQ-DI (score ± SD) | 1.69 ± 0.57 |
| Baseline therapies: | |
| Prednisone use (%) | 70.1 |
| MTX and steroids (%) | 53.7 |
| DMARDs other than MTX plus steroids (%) | 16.4 |
| MTX monotherapy (%) | 16.4 |
| DMARDs combination (not including MTX) (%) | 13.5 |
| Duration of non-biological therapy (years ± SD) | 4.63 (5.42) |

Legend: SD, standard deviation; BMI, body mass index; RA, rheumatoid arthritis; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; DMARDs, disease-modifying anti-rheumatic drugs.
Effect of Adalimumab on Work Ability Assessed in Rheumatoid Arthritis Disease Patients

Table 2. WPAI, HAQ-DI, FSS, and VAS-F outcomes before and after adalimumab therapy.

| Parameter                              | Baseline (Mean ± SD) | 6-Months Therapy (Mean ± SD) | p-Value |
|----------------------------------------|----------------------|------------------------------|---------|
| Absenteeism (%)                        | 21.64 ± 11.62        | 11.60 ± 11.17                | <0.0001 |
| Hours missed due to RA                 | 24.35 ± 12.31        | 11.01 ± 10.63                | <0.0001 |
| Hours missed for other reasons         | 3.03 ± 1.55          | 2.65 ± 1.47                  | 0.008   |
| Presenteeism (%)                       | 62.15 ± 20.11        | 34.92 ± 20.61                | <0.0001 |
| Degree of RA-affected productivity at work | 6.31 ± 1.89          | 3.49 ± 2.078                 | <0.0001 |
| Degree of RA-affected non-work activities | 6.95 ± 1.68          | 3.65 ± 2.095                 | <0.0001 |
| Overall work impairment (%)            | 69.08 ± 18.86        | 40.73 ± 22.29                | <0.0001 |
| Overall activity impairment (%)        | 68.46 ± 18.58        | 36.46 ± 20.79                | <0.0001 |
| HAQ-DI score                           | 1.69 ± 0.57          | 0.81 ± 0.61                  | <0.0001 |
| FSS score                              | 47.08 ± 9.55         | 27.86 ± 13.43                | <0.0001 |
| VAS-F score                            | 5.35 ± 1.86          | 4.52 ± 2.62                  | 0.079   |

Legend: WPAI, Work Productivity and Activity Impairment; HAQ-DI, Health Assessment Questionnaire-Disability Index; RA, rheumatoid arthritis; FSS, Fatigue Severity Score; VAS-F, Visual Analog Scale for Fatigue.

Notably, effective early treatment, which is becoming increasingly feasible, can avoid the need for later initiatives to facilitate re-employment of RA patients.

Our results also demonstrated that adalimumab had a beneficial effect on general fatigue. However, even though the FSS questionnaire revealed a clinically relevant improvement in the fatigue of adalimumab-treated RA patients, the VAS-F assessment did not. While the reason for this discrepancy remains unclear, our positive findings obtained with the FSS questionnaire are in agreement with results from a randomized clinical trial using the Functional Assessment of Chronic Illness Therapy fatigue scale [27].

This study presented some limitations. Indeed, the small sample size may not have been adequate for drawing significant conclusions. Moreover, this study did not include a control arm in order to confirm the specificity of the adalimumab effect. In addition, longer follow-up may be needed to confirm the long-term effects of this treatment strategy on work ability and fatigue. In this regard, controlled studies evaluating more patients with a longer follow-up are needed to demonstrate the long-term effects of adalimumab on work disability, as well as the potential cost-effectiveness of TNF inhibitors.

CONCLUSION

In this study, we have shown that work ability, functional disability, and fatigue improved after 6 months of adalimumab therapy in patients with established RA. To translate work ability into actual employment, there is a need to apply early and comprehensive disease control measures in order to maintain work ability and avoid the need for re-employment. Given the importance of improving work ability in patients with RA, and the results of this study, new trials on TNF inhibitors should consider including work ability assessments and fatigue scales as relevant outcomes for RA patients.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank the members of the Patient Support Program (Amira Farid, Samar Elwy, Nadeen Gebril, Rania Bassioni, Hoda Azzam, Enas Abdeldaim, Heba Bakir) for their help with the conduct of this study.

DISCLOSURES/FUNDING SOURCES

This study was supported by grants from AbbVie and Alzaidi Chair of Research in Rheumatic Diseases at Umm Alqura University, Makkah, Saudi Arabia. However, these funding sources had no involvement in the design of the study or the collection, analysis, and interpretation of data. Moreover, they did not influence the writing of the report or the decision to submit for publication.

REFERENCES

[1] Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006; 56(1): 18-27.
[2] Suurmeijer TP, Waltz M, Moun T, et al. Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum 2001; 45(2): 111-21.
[3] Mancuso CA, Rincon M, Sayles W, Paget SA. Psychosocial variables and fatigue: a longitudinal study comparing individuals with rheumatoid arthritis and healthy controls. J Rheumatol 2006; 33(8): 1496-502.
[4] Maetzl A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004; 63(4): 395-401.
This Received:

The European League Against Rheumatism collaborative initiative.

An American College of Rheumatology/ACR classification criteria: an American College of Rheumatology/ACR systemic lupus erythematosus. Arch Rheum 2008; 59(4): 510-4.

Regrettably, we are unable to reproduce the full data or images here.

[5] Allaire S, Wolfe F, Niu J, Lalvaley M, Michaud K. Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum 2005; 53(4): 603-8.

[6] Verstappen SM, Bijlsma JW, Verkleij H, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004; 51(3): 488-97.

[7] Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum 2008; 59(4): 510-4.

[8] Weinblatt ME, Keystone EC, Burz DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65(6): 753-9.

[9] Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology (Oxford) 2004; 43(6): 712-8.

[10] Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009; 68(6): 930-7.

[11] Almoallim H, Kamil A. Rheumatoid arthritis: should we shift the focus from "Treat to Target" to "Treat to Work"? Clin Rheumatol 2013; 32(3): 285-7.

[12] Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4(5): 353-65.

[13] Reilly M, Brown M, Brabant Y, Gerlier L, Tan S, Sandborn W. Defining the minimally important difference for WPAI: CD Scores: What is a relevant impact on work productivity in active Crohn's disease. Gut 2007; 56(Suppl 3): A159.

[14] Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30(1): 167-78.

[15] Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46(10): 1121-3.

[16] Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res 1991; 36(3): 291-8.

[17] Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69(9): 1580-8.

[18] Janoudi N, Almoallim H, Husien W, Noorwali A, Ibrahim A. Work ability and work disability evaluation in Saudi patients with rheumatoid arthritis. Special emphasis on work ability among housewives. Saudi Med J 2013; 34(11): 1167-72.

[19] Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36(6): 729-40.

[20] Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. J Rheumatol 2005; 32(11): 2250-6.

[21] van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39(1): 34-40.

[22] Hoving JL, Bartelds GM, Sluijer JK, et al. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol 2009; 38(4): 246-50.

[23] Kinel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008; 35(2): 206-15.

[24] de Croon EM, Sluijer JK, Nijsen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2004; 63(11): 1362-7.

[25] Puolakka K, Kautiainen H, Mottonen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52(1): 36-41.

[26] Welsing PM, Landewe RB, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50(7): 2082-93.

[27] Yount S, Sorenson MV, Cell D, Sengupta N, Grober J, Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007; 25(6): 838-46.